| Managing incidental findings in human subjects research: analysis and recommendations SM Wolf, FP Lawrenz, CA Nelson, JP Kahn, MK Cho, EW Clayton, ... Journal of Law, Medicine & Ethics 36 (2), 219-248, 2008 | 861 | 2008 |
| The law of incidental findings in human subjects research: establishing researchers' duties SM Wolf, J Paradise, C Caga-Anan Journal of Law, Medicine & Ethics 36 (2), 361-383, 2008 | 153 | 2008 |
| Regulating nanomedicine at the food and drug administration J Paradise AMA journal of ethics 21 (4), 347-355, 2019 | 85 | 2019 |
| European opposition to exclusive control over predictive breast cancer testing and the inherent implications for US patent law and public policy: A case study of the myriad … J Paradise Food & Drug LJ 59, 133, 2004 | 78 | 2004 |
| Gene patents: the need for bioethics scrutiny and legal change LB Andrews, J Paradise Yale J. Health Pol'y L. & Ethics 5, 403, 2005 | 73 | 2005 |
| An integrated approach to oversight assessment for emerging technologies J Kuzma, J Paradise, G Ramachandran, JA Kim, A Kokotovich, SM Wolf Emerging Technologies, 249-271, 2020 | 71 | 2020 |
| Recommendations for oversight of nanobiotechnology: dynamic oversight for complex and convergent technology G Ramachandran, SM Wolf, J Paradise, J Kuzma, R Hall, E Kokkoli, ... Emerging Technologies, 379-405, 2020 | 68 | 2020 |
| Patents on human genes: an analysis of scope and claims J Paradise, L Andrews, T Holbrook Science 307 (5715), 1566-1567, 2005 | 55 | 2005 |
| Exploring emerging nanobiotechnology drugs and medical devices J Paradise, GM Diliberto, AW Tisdale, E Kokkoli Food & Drug LJ 63, 407, 2008 | 42 | 2008 |
| Evaluating oversight of human drugs and medical devices: a case study of the FDA and implications for nanobiotechnology J Paradise, AW Tisdale, RF Hall, E Kokkoli Journal of Law, Medicine & Ethics 37 (4), 598-624, 2009 | 39 | 2009 |
| Electronic cigarettes: smoke-free laws, sale restrictions, and the public health J Paradise American journal of public health 104 (6), e17-e18, 2014 | 38 | 2014 |
| Developing US oversight strategies for nanobiotechnology: learning from past oversight experiences J Paradise, SM Wolf, J Kuzma, A Kuzhabekova, AW Tisdale, E Kokkoli, ... Journal of Law, Medicine & Ethics 37 (4), 688-705, 2009 | 33 | 2009 |
| Developing oversight frameworks for nanobiotechnology J Paradise, SM Wolf, G Ramachandran, E Kokkoli, R Hall, J Kuzma Minn. JL Sci. & Tech. 9, 399, 2008 | 33 | 2008 |
| When patents threaten science L Andrews, J Paradise, T Holbrook, D Bochneak Science 314 (5804), 1395-1396, 2006 | 32 | 2006 |
| Constructing ethical guidelines for biohistory LB Andrews, N Buenger, J Bridge, L Rosenow, D Stoney, RE Gaensslen, ... Science 304 (5668), 215-216, 2004 | 31 | 2004 |
| Reassessing safety for nanotechnology combination products: what do biosimilars add to regulatory challenges for the FDA J Paradise . Louis ULJ 56, 465, 2011 | 27 | 2011 |
| Synthetic biology: Does re-writing nature require re-writing regulation J Paradise, E Fitzpatrick Penn St. L. Rev. 117, 53, 2012 | 26 | 2012 |
| The legal and regulatory status of biosimilars: how product naming and state substitution laws may impact the United States healthcare system J Paradise American Journal of Law & Medicine 41 (1), 49-84, 2015 | 23 | 2015 |
| REMS as a Competitive Tactic: Is Big Pharma Hijacking Drug Access and Patient Safety J Paradise Hous. J. Health L. & Pol'y 15, 43, 2015 | 22 | 2015 |
| Claiming nanotechnology: improving USPTO efforts at classification of emerging nano-enabled pharmaceutical technologies J Paradise Nw. J. Tech. & Intell. Prop. 10, 169, 2011 | 22 | 2011 |
